- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00127972
2NN & CHARM Long-Term Follow-up Study
A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 2NN study has been completed, the first large randomised trial comparing the efficacy and safety of ART containing two nucleoside analogue reverse transcriptase inhibitors (nRTI: d4T+3TC) and either NVP-od, NVP-bd, EFV or the combination of NVP+EFV in the treatment of chronically HIV-1 infected ART naive patients. Data from this randomized study show no significant differences in response to treatment, and virologic and immunologic efficacy in the single NNRTI arms NVP-od, NVP-bd and EFV. This contrasts with previous cohort studies, which showed a relative hazard in virologic or treatment failure of more than two for those starting with NVP compared to those starting with EFV.
Despite the results of the 2NN study, question remains whether the comparability of NVP and EFV is maintained over a longer period of follow-up. Therefore, this study is designed to assess the durability of the efficacy of the regimens used in the 2NN study.
In the initial CHARM study, the effect of adding nevirapine and/or hydrea to a triple NRTI regimen (trizivir i.e. abacavir, lamivudine and zidovudine) in terms of efficacy and tolerability was investigated in anti retroviral naïve patients. The primary endpoint was treatment failure and follow up was 72 weeks. A total of 229 patients were included. The use of hydrea was prematurely stopped because adding hydrea significantly contributed to treatment failure through enhancement of the toxicities associated with its use. Subjects in the nevirapine group reached a plasma HIV-1 RNA level < 50 copies/ml quicker (log rank test p = 0.011). In addition, in an as treated analysis only 16.2% of subjects adding nevirapine versus 39.5% adding no nevirapine reached the primary endpoint (p=0.027). These results resemble the findings in the ACTG A5059 study. The trizivir arm of this ACTG study was stopped, because anti-retroviral naïve subjects randomized to receive trizivir experienced virological failure earlier and more frequent than subjects who were randomized to receive either of the two other treatment regimens being evaluated in that study. The two other treatment regimens were:
- a combination of zidovudine plus lamivudine plus efavirenz and
- trizivir plus efavirenz.
It is desirable to obtain extended follow up data on subjects who participated in the CHARM study in order to see if the beneficial effect of adding nevirapine to trizivir continues or even increases after 72 weeks of treatment.
In addition to this main objective, another important issue regards the known association between the use of nevirapine and the occurrence of certain untoward effects, including the development of rash, clinical hepatitis and a hypersensitivity syndrome which usually presents with rash, elevated alanine aminotransferase and/or aspartate aminotransferase, eosinophilia and a host of other constitutional symptoms. The possibility that a metabolite of nevirapine might be responsible for one or the other of these events has been evaluated but could not be confirmed. Data is equivocal on whether nevirapine levels themselves are associated with these events, probably because of "noise" in the retrospective analyses that was used. Animal models would suggest, though, that supratherapeutic nevirapine levels are associated with these events. It seems reasonable to assume that there is a sub-population of people at risk for all of these events (especially hypersensitivity) based on their genetic make-up in that it is known that many patients easily tolerate significantly elevated levels of nevirapine while others may get these side effects with relatively normal levels.
To facilitate the safe administration of nevirapine to patients, this study also aims to identify a gene or genes closely associated with these events, and from that a phenotype associated with that genotype which is at increased risk.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Darlinghurst, Australia, NSW2010
- Holdsworth House Medical Practice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participation in the original 2NN or CHARM study
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine whether the number of patients with treatment failure after 144 weeks of follow-up is different between study arms
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine whether the percentage of patients with treatment failure after 144 weeks of follow-up is different between the treatment arms
|
To determine whether the percentage of patients with virologic failure after 144 weeks of follow-up is different between the treatment arms
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Joep MA Lange, MD PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Principal Investigator: Mark Bloch, MD, Holdsworth House General Practice
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Nevirapine
- Lamivudine
- Stavudine
- Efavirenz
Other Study ID Numbers
- 04IAT0035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on efavirenz
-
Institut BergoniéCompletedNon-Hodgkin's Lymphoma | Solid TumorsFrance
-
St Stephens Aids TrustViiV HealthcareUnknown
-
Herlev HospitalFlexdialysis ApSCompleted
-
Shanghai Public Health Clinical CenterNot yet recruitingHIV Infections | Tuberculosis
-
University Hospital, Basel, SwitzerlandUniversity of BaselCompletedBiological Availability | Amorphous Solid DispersionsSwitzerland
-
Peking Union Medical College HospitalUnknownHIV/AIDS | Mental ImpairmentChina
-
Yale UniversityTerminatedSafety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic HypotensionHemodialysis | HypotensionUnited States
-
Center for Clinical Pharmacology Research Bdbeq...University of the Republic, UruguayCompleted
-
Stanford UniversityTerminatedHIV Infections | TuberculosisBrazil
-
Kirby InstituteCompleted